Jefferies Raises BioMarin (BMRN) Stock Price Target on Settlement

Jefferies has increased the stock price target for BioMarin Pharmaceuticals (BMRN) following the settlement related to Ascendis. This new target reflects an adjustment based on the settlement's implications for BioMarin’s market position and future earnings. The specific new price target was not mentioned in the article. This adjustment may influence investor sentiment and stock performance, making it relevant for current and potential shareholders in BioMarin.